Canaud Ludovic, D'Annoville Thomas, Ozdemir Baris Ata, Marty-Ané Charles, Alric Pierre
Department of Thoracic and Vascular Surgery, Arnaud de Villeneuve Hospital, and Unité INSERM U1046, Montpellier, France.
Department of Thoracic and Vascular Surgery, Arnaud de Villeneuve Hospital, and Unité INSERM U1046, Montpellier, France.
J Thorac Cardiovasc Surg. 2014 Nov;148(5):2108-11. doi: 10.1016/j.jtcvs.2014.01.018. Epub 2014 Jan 21.
The perioperative outcomes of the endovascular approach to aortobronchial fistula have been favorable. However, it is uncertain whether thoracic endovascular aneurysm repair (TEVAR) alone provides a complete and durable cure for an aortobronchial fistula. TEVAR does nothing to address the issue of the defect in the respiratory tract, leaving the patient at risk of aortobronchial fistula recurrence and/or stent graft infection. The authors believe that the bronchial defect should be addressed.
Over the last 10 years, 5 patients were treated for an aortobronchial fistula using a combined endovascular and surgical approach (primary treatment in 3 patients and secondary after TEVAR in 2 patients). All the patients underwent emergency stent graft placement and concomitant (n=1) or staged (n=4) open repair including pulmonary resection with coverage of the stent graft using muscle or pleural flaps. All patients received a 6-week course of broad-spectrum intravenous antibiotics followed by lifelong oral antibiotics.
All patients survived the surgical procedure. After a mean follow-up of 23.2 months, 4 patients are asymptomatic and postprocedure computed tomography scans were unremarkable. One patient treated for an aortobronchial fistula after TEVAR was readmitted 4 months after surgical conversion. Stent graft explantation and silver-coated tube graft replacement of the descending thoracic aorta were performed for severe mediastinitis with associated thoracic stent graft infection. The postoperative course of this patient was uneventful.
Emergency TEVAR for an aortobronchial fistula is an appealing strategy for this devastating complication. However, to achieve a lasting result, direct contact between the stent graft and the pulmonary tissue should be avoided to prevent further erosive damage. Concomitant or staged repair should entail primary repair or resection and anastomosis of the bronchus and/or pulmonary resection with coverage of the stent graft using muscle or pleural flaps combined with broad-spectrum intravenous antibiotic therapy. Long-term surveillance and continued investigation are warranted.
血管腔内治疗主动脉支气管瘘的围手术期结果良好。然而,单纯的胸主动脉腔内修复术(TEVAR)是否能完全且持久地治愈主动脉支气管瘘尚不确定。TEVAR无法解决呼吸道缺损问题,使患者面临主动脉支气管瘘复发和/或支架移植物感染的风险。作者认为应处理支气管缺损。
在过去10年中,5例患者采用血管腔内与外科联合方法治疗主动脉支气管瘘(3例为初次治疗,2例为TEVAR术后二次治疗)。所有患者均接受了急诊支架移植物置入,并同时(n = 1)或分期(n = 4)进行开放修复,包括肺切除,并用肌肉或胸膜瓣覆盖支架移植物。所有患者接受为期6周的广谱静脉抗生素治疗,随后终身口服抗生素。
所有患者均在手术中存活。平均随访23.2个月后,4例患者无症状,术后计算机断层扫描无异常。1例TEVAR术后治疗主动脉支气管瘘的患者在手术转换4个月后再次入院。因严重纵隔炎伴相关胸段支架移植物感染,进行了支架移植物取出术及降主动脉银涂层人工血管置换术。该患者术后过程顺利。
对于这种严重并发症,急诊TEVAR治疗主动脉支气管瘘是一种有吸引力的策略。然而,为获得持久效果,应避免支架移植物与肺组织直接接触,以防止进一步的侵蚀性损伤。同时或分期修复应包括支气管的一期修复或切除及吻合和/或肺切除,并用肌肉或胸膜瓣覆盖支架移植物,同时联合广谱静脉抗生素治疗。需要进行长期监测和持续研究。